Search & Analyze

Sun Pharmaceutical Industries Ltd.

HealthcarePharmaceuticals & Drugs

www.sunpharma.com BSE: 524715NSE: SUNPHARMA

₹1,899.80BSE0.20%

07 Sep, 4:01 PM

₹1,899.80

₹4.56L Cr

37.69

5.27

14.85%

₹1,907.35

₹1,882.85

₹2,047.55

₹1,547.25

Customise metrics bar

Price Performance

Peer Comparison

Name
Sun Pharmaceutical Industries Ltd. SUNPHARMA	1,899.80	37.69	4,55,825.66	0.84	2,901.23	26.53%	15,299.88	10.46%	19.11
DIVI'S LAB. DIVISLAB	9,305.00	84.45	2,47,018.51	0.32	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,913.00	85.68	1,86,874.73	0.77	566.00	3.28%	4,921.00	54.85%	19.27
ZYDUSLIFE ZYDUSLIFE	1,155.00	25.53	1,15,211.69	0.09	990.20	-34.90%	8,017.00	21.96%	21.39
CIPLA LTD. CIPLA	1,395.95	33.46	1,12,773.00	0.93	785.55	-39.18%	7,119.28	2.33%	16.00
LAURUSLABS LAURUSLABS	1,868.25	92.32	1,00,943.83	0.11	362.07	123.94%	2,026.31	29.10%	18.20
LUPIN LTD. LUPIN	2,105.00	17.41	96,254.46	0.86	1,416.98	16.01%	8,276.89	32.04%	28.86
MANKIND MANKIND	2,322.05	46.95	95,911.14	0.04	574.09	29.12%	4,030.59	12.89%	13.24

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	11,982.90	12,652.75	13,291.39	13,675.46	12,958.84	13,851.40	14,478.31	15,520.54	14,611.79	15,299.88
Expenses	8,947.75	9,045.13	9,480.52	9,666.44	9,242.75	9,549.74	10,381.73	10,725.97	10,657.59	10,882.21
	3,035.15	3,607.62	3,810.87	4,009.02	3,716.09	4,301.66	4,096.58	4,794.57	3,954.20	4,417.67
	25.33%	28.51%	28.67%	29.32%	28.68%	31.06%	28.29%	30.89%	27.06%	28.87%
	504.30	532.55	482.09	149.45	251.19	-353.54	900.39	243.28	458.50	519.53
Interest	73.57	61.54	69.17	51.51	49.14	74.80	99.86	78.36	85.89	99.67
	650.36	655.13	625.91	630.56	663.79	700.55	729.50	732.33	775.47	738.72
	2,807.67	3,412.76	3,604.54	3,471.84	3,247.64	3,163.02	4,155.47	4,207.24	3,537.28	4,089.24
	5.30%	16.18%	15.74%	16.10%	33.68%	27.51%	24.80%	19.63%	23.40%	29.05%
	2,654.58	2,835.62	3,040.16	2,903.38	2,149.88	2,278.63	3,117.95	3,368.81	2,714.03	2,894.79
	11.06	11.82	12.67	12.10	8.96	9.50	13.00	14.04	11.31	12.07

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	67,191.41	43,885.68	48,496.85	52,578.44	58,462.04
	38,654.49	43,885.68	48,496.85	52,578.44	58,462.04
EXPENDITURE :
Increase/Decrease in Stock	-107.61	-686.91	292.13	150.31	343.13
Raw Material Consumed	10,459.15	11,349.07	10,370.48	10,597.05	11,200.55
Power & Fuel Cost	702.78	830.05	760.78	750.40	813.66
Employee Cost	7,300.83	8,296.03	9,429.06	9,973.12	11,418.86
Other Manufacturing Expenses	1,880.71	1,936.77	2,186.62	2,261.24	2,564.42
General and Administration Expenses	3,270.55	4,256.12	5,252.93	5,646.06	6,082.90
Selling and Distribution Expenses	4,096.33	5,226.24	5,780.26	6,576.86	7,748.24
Miscellaneous Expenses	1,169.94	1,090.75	1,675.51	1,537.24	1,799.06
	28,772.68	32,298.12	35,747.77	37,492.28	41,970.82
Operating Profit (Excl OI)	9,881.81	11,587.56	12,749.08	15,086.16	16,491.22
	1,437.42	693.75	1,628.24	2,150.57	3,211.90
	11,319.23	12,281.31	14,377.32	17,236.73	19,703.12
Interest	127.35	172.00	238.47	231.36	338.91
PBDT	11,191.88	12,109.31	14,138.85	17,005.37	19,364.21
	2,143.74	2,529.43	2,556.64	2,575.39	2,937.85
Profit Before Taxation & Exceptional Items	9,048.14	9,579.88	11,582.21	14,429.98	16,426.36
Exceptional Income / Expenses	-4,566.82	-171.45	-494.32	-677.85	-1,307.48
	4,481.32	9,408.43	11,087.89	13,752.13	15,118.88
Provision for Tax	1,075.50	847.59	1,439.45	2,772.03	3,554.36
	3,405.82	8,560.84	9,648.44	10,980.10	11,564.52
Extra items				0.00	0.00
Minority Interest	-116.55	-39.36	-33.65	-35.71	-29.23
Share of Associate	-16.54	-47.90	-38.41	-15.35	-55.87
Consolidated Net Profit	3,272.73	8,473.58	9,576.38	10,929.04	11,479.42
Profit Balance B/F	36,598.09	37,645.65	43,610.25	50,154.55	57,861.84
Appropriations	39,870.82	46,119.23	53,186.63	61,083.59	69,341.26
Equity Dividend %	1,000.00%	1,150.00%	1,350.00%	1,600.00%	1,600.00%
	13.64	35.32	39.91	45.55	47.84
Adjusted EPS	13.64	35.32	39.91	45.55	47.84

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	239.93	239.93	239.93	239.93	239.93
Total Reserves	47,771.29	55,755.45	63,426.82	71,978.09	83,330.16
Reserve excluding Revaluation Reserve	47,771.29	55,755.45	63,426.82	71,978.09	83,330.16
	48,011.22	55,995.38	63,666.75	72,218.02	83,570.09
Minority Interest	3,054.89	3,320.09	3,459.19	267.93	309.65
Unsecured Loans	229.92		1.33	2.52	31.26
Deferred Tax Assets / Liabilities	-2,817.72	-3,487.23	-3,931.79	-4,215.11	-3,668.44
Other Long Term Liabilities	902.36	1,146.52	802.23	751.66	1,349.09
Long Term Provisions	369.07	342.91	413.89	473.80	525.07
Total Non-Current Liabilities	-1,316.37	-1,997.80	-2,714.34	-2,987.13	-1,763.02
Trade Payables	4,489.76	5,681.52	5,653.30	6,184.34	7,333.80
Other Current Liabilities	2,926.73	2,603.51	2,716.85	3,254.45	3,943.79
Short Term Borrowings	468.52	5,958.26	2,844.36	1,867.11	4,050.35
Short Term Provisions	9,323.44	5,663.09	5,769.26	6,888.31	7,294.10
Total Current Liabilities	17,208.45	19,906.38	16,983.77	18,194.21	22,622.04
Total Liabilities	66,958.19	77,224.67	81,396.00	87,693.03	1,04,738.76
Gross Block	38,707.36	43,099.95	44,320.48	45,949.61	60,321.41
Less: Accumulated Depreciation	16,042.20	19,034.51	21,072.33	23,363.33	27,499.14
Net Block	22,665.16	24,065.44	23,248.15	22,586.28	32,822.27
Capital Work in Progress	797.51	963.35	1,107.73	1,234.34	1,380.65
Non Current Investments	5,214.65	5,451.73	6,441.23	4,697.70	3,789.07
Long Term Investment	5,214.65	5,451.73	6,441.23	4,697.70	3,789.07
Long Term Loans & Advances	2,880.86	2,757.87	2,784.59	1,016.49	1,132.77
Other Non Current Assets	46.12	93.13	93.17	124.13	51.73
Total Non-Current Assets	32,093.59	37,341.33	37,921.02	35,068.56	40,847.57
Currents Investments	7,633.94	9,372.61	8,584.54	13,656.10	20,933.45
Inventories	8,925.13	10,513.05	9,868.29	10,243.33	11,492.93
Sundry Debtors	10,484.59	11,438.51	11,249.37	13,046.11	15,509.67
Cash and Bank	5,033.35	5,770.29	10,520.68	11,331.62	11,603.08
Other Current Assets	775.01	745.91	755.99	624.54	715.15
Short Term Loans and Advances	2,012.58	2,021.57	2,454.24	3,692.36	3,606.01
Total Current Assets	34,864.60	39,861.94	43,433.11	52,594.06	63,860.29
Net Current Assets (Including Current Investments)	17,656.15	19,955.56	26,449.34	34,399.85	41,238.25
Total Assets	66,958.19	77,224.67	81,396.00	87,693.03	1,04,738.76
Contingent Liabilities	3,647.11	4,061.31	4,567.19	4,276.02	1,587.05
Total Debt	930.69	6,197.88	2,845.69	1,869.63	4,081.61
	200.11	233.38	265.36	301.00	348.31
Adjusted Book Value	200.11	233.38	265.36	301.00	348.31

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	4,481.32	9,408.43	11,087.89	13,752.13	15,118.88
Adjustment	1,974.95	2,722.56	1,554.40	1,120.36	882.03
Changes In working Capital	1,559.05	-5,661.82	1,062.13	-323.56	-1,267.79
Cash Flow after changes in Working Capital	8,015.32	6,469.17	13,704.42	14,548.93	14,733.12
Cash Flow from Operating Activities	8,984.54	4,959.33	12,134.98	14,072.09	12,419.18
Cash Flow from Investing Activities	-5,724.74	-7,943.68	-690.20	-5,306.16	-11,344.05
Cash Flow from Financing Activitie	-5,193.46	2,376.07	-6,710.16	-7,905.82	-2,512.55
Net Cash Inflow / Outflow	-1,933.66	-608.28	4,734.62	860.11	-1,437.42
Opening Cash & Cash Equivalents	6,273.03	4,508.25	4,623.73	9,285.65	10,268.77
Cash & Cash Equivalent of Subsidiaries under liquidations	41.45	566.69	1.29	-0.03	162.73
Effect of Foreign Exchange Fluctuations	127.43	157.07	-73.99	123.04	776.43
Closing Cash & Cash Equivalent	4,508.25	4,623.73	9,285.65	10,268.77	9,770.51

Ratios

Valuation

37.69

5.27

22.33

7.65

50.41

360.44

Profitability

14.85

19.11

12.02

28.21

19.78

Leverage & Liquidity

0.05

2.82

45.61

Returns

0.84

0.61

Shareholding Pattern

Numbers in percentages

Particulars	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26
	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48	54.48
	36.51	36.62	36.59	36.66	36.75	36.78	36.93	37.04	36.70
	9.02	8.90	8.93	8.87	8.77	8.73	8.58	8.48	8.82
	45.52	45.52	45.52	45.52	45.52	45.52	45.52	45.52	45.52
No. of Shareholders	6,73,217	6,57,317	6,89,623	7,04,983	7,23,770	7,43,877	7,10,900	6,90,957	7,10,246

Corporate Actions

Showing: All

Date	Type	Details	Ex-Date	Record Date
2026-07-10	Board Meeting	Quarterly Results
2026-07-06	AGM
2026-05-22	Ex Dividend	Rs.5.0000 per share(500%)Final Dividend	2026-07-07	2026-07-07

Insider Trading

Date	Person	Category	Transaction Type	Shares	Value (₹)

No insider trading data available.

Sector Overview

HealthcarePharmaceuticals & Drugs

Sun Pharmaceutical Industries Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

12 members across the board and senior leadership

Anoop Deshpande

Company Secretary & Compliance Officer

—

Dilip Shantilal Shanghvi

Chairman

₹7.05 Cr

Mar '26

Dilip S Shanghvi

Chairman & Managing Director

₹6.48 Cr

Mar '25

Kirti Ganorkar

Managing Director

₹5.87 Cr

Mar '26

Gautam Doshi

Non Executive Independent Director

₹96.00 L

Mar '26

Rolf Hoffmann

Non Executive Independent Director

₹66.00 L

Mar '26

Aalok Shanghvi

Whole Time Director & Chief Operating Officer

₹9.33 Cr

Mar '26

Pawan Goenka

Lead Independent Director

₹1.09 Cr

Mar '26

Rama Bijapurkar

Non Executive Independent Director

₹68.00 L

Mar '25

Satyavati Berera

Non Executive Independent Director

—

Vidhi Shanghvi

Whole Time Director & Head - CHC

₹2.00 Cr

Mar '26

Andreas Eugen Busch

Non Executive Independent Director

—

SUNPHARMA Latest News

News

10 of 10 articles

EQUITY1 Sept 2026 · 09:40

Sun Pharmaceutical Industries informs about press release

EQUITY17 Aug 2026 · 09:35

Sun Pharmaceutical Industries informs about update

COMPANY31 Jul 2026 · 18:02

Sun Pharma reports 27% rise in Q1 consolidated net profit

Consolidated total income of the company increased by 11.93% to Rs 16,023.50 crore for Q1FY27

EQUITY30 Jul 2026 · 09:42

Sun Pharm moves up on getting nod to manufacture, market semaglutide in Brazil

The company plans to launch the product in the next few days in partnership with Hypera Pharma, a leading pharmaceutical company in Brazil

COMPANY30 Jul 2026 · 09:29

Sun Pharm gets nod to manufacture, market semaglutide in Brazil

The company plans to launch the product in the next few days in partnership with Hypera Pharma, a leading pharmaceutical company in Brazil

EQUITY24 Jul 2026 · 09:17

Sun Pharmaceutical Industries informs about press release

EQUITY15 Jul 2026 · 11:06

Sun Pharma rises on getting nod to manufacture, market generic semaglutide in South Africa

The company has secured approval from the South African Health Products Regulatory Authority

COMPANY15 Jul 2026 · 10:43

Sun Pharma gets nod to manufacture, market generic semaglutide in South Africa

The company has secured approval from the South African Health Products Regulatory Authority

EQUITY15 Jul 2026 · 09:39

Sun Pharmaceutical Industries informs about press release

EQUITY23 Jun 2026 · 14:54

Sun Pharma gains on BSE

The company has entered into an agreement to acquire Innovcare Lifesciences

SUNPHARMA

₹1,899.80

+0.2%